Price Alert: Shares of Polypid (PYPD) Trade 6.97% Higher at Midday June 23

Equities Staff  |

Today Polypid Ltd (NASDAQ: PYPD) is trading 6.97% higher.

The latest price, as of 11:17:26 est, was $4.91. Polypid has climbed $0.32 over the previous day’s close.

1,108 shares have exchanged hands.

As of the previous close, Polypid has a YTD change of 20.03%. The company anticipates its next earnings on 2022-08-10.

For technical charts, analysis, and more on Polypid visit the company profile.

About Polypid Ltd

PolyPid Ltd. is a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enables precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

To get more information on Polypid Ltd and to follow the company's latest updates, you can visit the company's profile page here: Polypid Ltd's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content